Adam Feinberg,
CTO and Co-founder, FluidForm Inc., Professor of Biomedical Engineering,
Carnegie Mellon University
Dr. Adam Feinberg is Co-Founder and CTO of FluidForm Inc, a start-up company commercializing FRESH 3D bioprinting technology, and a Professor at Carnegie Mellon University in the departments of Biomedical Engineering and Materials Science & Engineering. He earned his BS in Materials Science & Engineering from Cornell University in 1999 with Co-op experience at Abiomed, Inc., working on total artificial hearts. He then earned his PhD in Biomedical Engineering from the University of Florida, focused on engineering cell-material interactions to prevent and enhance adhesion. This was followed by postdoctoral training at Harvard University, developing new biomaterials and stem cell-based cardiac tissue engineering strategies. Dr. Feinberg has co-authored over 50 peer-reviewed publications, holds over 20 US patents and patent applications and has received multiple honors including the NSF CAREER Award, the NIH Director’s New Innovator Award, and Fellow of the American Institute for Medical and Biological Engineering. A primary research focus is engineering extracellular matrix (ECM) protein scaffolds using advanced biomanufacturing and 3D bioprinting approaches for multiple applications including cancer models, regenerative scaffolds, skeletal muscle and cardiac muscle tissue engineering. At FluidForm, he is driving the commercialization of the FRESH 3D bioprinting platform for a wide range of applications in the biopharma, medical device, and regenerative medicine industries.
Engineering Functional Human Tissue Using FRESH 3D Bioprinting
Monday, 7 November 2022 at 09:00
Add to Calendar ▼2022-11-07 09:00:002022-11-07 10:00:00Europe/LondonEngineering Functional Human Tissue Using FRESH 3D BioprintingBioprinting and Bioink Innovations for 3D-Tissues 2022 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
At FluidForm we are working to expand 3D bioprinting from a niche technology and into a versatile platform for fabricating functional human tissues with complex geometries and features ranging from the cellular to organ length scales. We are different because we are addressing limitations with current approaches with a specific focus on improving the structure and function of the engineered tissue constructs. To do this, we have developed novel biofabrication approaches focused on building extracellular matrix (ECM) scaffolds that mimic the structure and composition of the heart and other tissues and organs. Termed Freeform Reversible Embedding of Suspended Hydrogels (FRESH), we can 3D bioprint collagen, fibrin, decellularized ECM, growth factors, and a wide range of cell types into complex 3D architectures. This includes using FRESH to create small heart muscle constructs as a predictive model of cardiac electrophysiology all the way to large, organ-scale constructs based on patient-specific MRI scans that incorporate functional arteries and valves within full-size, whole hearts. Our focus at FluidForm is driving these applications into pharma and the clinic and extending these approaches to additional tissue and organ systems for in vitro disease modeling and in vivo regeneration.
Add to Calendar ▼2022-11-07 00:00:002022-11-08 00:00:00Europe/LondonBioprinting and Bioink Innovations for 3D-Tissues 2022Bioprinting and Bioink Innovations for 3D-Tissues 2022 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-11-07 09:00:002022-11-07 10:00:00Europe/LondonEngineering Functional Human Tissue Using FRESH 3D BioprintingBioprinting and Bioink Innovations for 3D-Tissues 2022 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
